Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
MENLO PARK, Calif., March 31, 2016 -- Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that Peter Staple, Corium's President and Chief Executive Officer, will present at the 15th Annual Needham Healthcare Conference in New York City on Tuesday, April 12, 2016 at 3:40 p.m. Eastern time.
A live audio broadcast of Corium’s presentation may be accessed under “Events & Presentations” in the Investors section of Corium’s website at www.coriumgroup.com. A webcast will be archived on the Corium website for two weeks following the presentation.
About Corium
Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company's broad experience with advanced transdermal and transmucosal delivery systems. Corium has developed and is the sole commercial manufacturer of seven prescription drug and consumer products with partners Teva Pharmaceuticals, Par Pharmaceutical and Procter & Gamble. The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor®, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. The company's late-stage pipeline includes a contraceptive patch co-developed with Agile Therapeutics that is currently in Phase 3 trials, and additional transdermal products that are being developed with other partners. Corium has multiple proprietary programs in preclinical and clinical development for the treatment of osteoporosis, and neurodegenerative and neurological disorders. For further information, please visit www.coriumgroup.com.
Corplex™ and MicroCor® are registered trademarks of Corium International, Inc.
Investor and Media Contact: Karen L. Bergman BCC Partners [email protected] (650) 575-1509
